Wolfe Research initiated coverage of Scholar Rock (SRRK) with an Outperform rating and $42 price target Scholar Rock’s manufacturing “hiccup is just a detour, not a derailment,” argues the analyst, who forecasts apitegromab to achieve blockbuster sales given its non-overlapping mechanism.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock price target raised to $45 from $44 at Barclays
- Scholar Rock’s Earnings Call: Optimism Amid Regulatory Challenges
- Buy Rating for Scholar Rock Holdings Driven by Strategic Preparations for Apitegromab’s Market Launch
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Scholar Rock Advances SMA Treatment Amid Financial Losses